ADAMAS PHARMACEUTICALS PRESENTS POSITIVE PHASE 2/3 RESULTS FOR ADS-5102 FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA (LID) IN PARKINSON’S DISEASE